Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant Carcinomas

por Bingham, Paul M., Zachar, Zuzana
Publicado 2023

A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process

por Stuart, Shawn D, Schauble, Alexandra, Gupta, Sunita, Kennedy, Adam D, Keppler, Brian R, Bingham, Paul M, Zachar, Zuzana
Publicado 2014

Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613

por Guardado Rivas, Moises O., Stuart, Shawn D., Thach, Daniel, Dahan, Michael, Shorr, Robert, Zachar, Zuzana, Bingham, Paul M.
Publicado 2022

A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer

por Alistar, Angela, Morris, Bonny B., Desnoyer, Rodwige, Klepin, Heidi D., Hosseinzadeh, Keyanoosh, Clark, Clancy, Cameron, Amy, Leyendecker, John, D’Agostino, Ralph, Topaloglu, Umit, Boteju, Lakmal W., Boteju, Asela R., Shorr, Rob, Zachar, Zuzana, Bingham, Paul M., Ahmed, Tamjeed, Crane, Sandrine, Shah, Riddhishkumar, Migliano, John J., Pardee, Timothy S., Miller, Lance, Hawkins, Gregory, Jin, Guangxu, Zhang, Wei, Pasche, Boris
Publicado 2017